1-7 of 7
Rashmi Chugh
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

A Multicenter Phase II Trial of Ipilimumab and Nivolumab in Unresectable or Metastatic Metaplastic Breast Cancer: Cohort 36 of Dual Anti–CTLA-4 and Anti–PD-1 Blockade in Rare Tumors (DART, SWOG S1609)

Sylvia Adams, Megan Othus, Sandip Pravin Patel, Kathy D. Miller, Rashmi Chugh, Scott M. Schuetze, Mary D. Chamberlin, Barbara J. Haley, Anna Maria V. Storniolo, Mridula P. Reddy, Scott A. Anderson, Collin T. Zimmerman, Anne P. O'Dea, Hamid R. Mirshahidi, Jordi Rodon Ahnert, Frank J. Brescia, Olwen Hahn, Jane M. Raymond, David D. Biggs, Roisin M. Connolly, Elad Sharon, Larissa A. Korde, Robert J. Gray, Edward Mayerson, Melissa Plets, Charles D. Blanke, Young Kwang Chae, Razelle Kurzrock
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (2): 271–278.
https://doi.org/10.1158/1078-0432.CCR-21-2182
Published: 19 January 2022
View article titled, A Multicenter Phase II Trial of Ipilimumab and Nivolumab in Unresectable or Metastatic Metaplastic Breast Cancer: Cohort 36 of Dual Anti–CTLA-4 and Anti–PD-1 Blockade in Rare Tumors (DART, SWOG S1609)
Open the PDF for A Multicenter Phase II Trial of Ipilimumab and Nivolumab in Unresectable or Metastatic Metaplastic Breast Cancer: Cohort 36 of Dual Anti–CTLA-4 and Anti–PD-1 Blockade in Rare Tumors (DART, SWOG S1609) in another window
Includes: Supplementary data
Journal Articles

Linsitinib (OSI-906) for the Treatment of Adult and Pediatric Wild-Type Gastrointestinal Stromal Tumors, a SARC Phase II Study

Margaret von Mehren, Suzanne George, Michael C. Heinrich, Scott M. Schuetze, Jeffrey T. Yap, Jain Q. Yu, Amanda Abbott, Samuel Litwin, John Crowley, Martin Belinsky, Katherine A. Janeway, Jason L. Hornick, Douglas B. Flieder, Rashmi Chugh, Lori Rink, Annick D. Van den Abbeele
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (8): 1837–1845.
https://doi.org/10.1158/1078-0432.CCR-19-1069
Published: 15 April 2020
View article titled, Linsitinib (OSI-906) for the Treatment of Adult and Pediatric Wild-Type Gastrointestinal Stromal Tumors, a SARC Phase II Study
Open the PDF for Linsitinib (OSI-906) for the Treatment of Adult and Pediatric Wild-Type Gastrointestinal Stromal Tumors, a SARC Phase II Study in another window
Journal Articles

A First-in-Human Phase I Study of the Anticancer Stem Cell Agent Ipafricept (OMP-54F28), a Decoy Receptor for Wnt Ligands, in Patients with Advanced Solid Tumors

Antonio Jimeno, Michael Gordon, Rashmi Chugh, Wells Messersmith, David Mendelson, Jakob Dupont, Robert Stagg, Ann M. Kapoun, Lu Xu, Shailaja Uttamsingh, Rainer K. Brachmann, David C. Smith
Journal: Clinical Cancer Research
Clin Cancer Res (2017) 23 (24): 7490–7497.
https://doi.org/10.1158/1078-0432.CCR-17-2157
Published: 14 December 2017
View article titled, A First-in-Human Phase I Study of the Anticancer Stem Cell Agent Ipafricept (OMP-54F28), a Decoy Receptor for Wnt Ligands, in Patients with Advanced Solid Tumors
Open the PDF for A First-in-Human Phase I Study of the Anticancer Stem Cell Agent Ipafricept (OMP-54F28), a Decoy Receptor for Wnt Ligands, in Patients with Advanced Solid Tumors in another window
Journal Articles

A Phase I Study of the Cyclin-Dependent Kinase 4/6 Inhibitor Ribociclib (LEE011) in Patients with Advanced Solid Tumors and Lymphomas

Jeffrey R. Infante, Philippe A. Cassier, John F. Gerecitano, Petronella O. Witteveen, Rashmi Chugh, Vincent Ribrag, Abhijit Chakraborty, Alessandro Matano, Jason R. Dobson, Adam S. Crystal, Sudha Parasuraman, Geoffrey I. Shapiro
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2016) 22 (23): 5696–5705.
https://doi.org/10.1158/1078-0432.CCR-16-1248
Published: 30 November 2016
View article titled, A Phase I Study of the Cyclin-Dependent Kinase 4/6 Inhibitor Ribociclib (LEE011) in Patients with Advanced Solid Tumors and Lymphomas
Open the PDF for A Phase I Study of the Cyclin-Dependent Kinase 4/6 Inhibitor Ribociclib (LEE011) in Patients with Advanced Solid Tumors and Lymphomas in another window
Includes: Supplementary data
Journal Articles

A Phase I Dose Escalation and Expansion Study of the Anticancer Stem Cell Agent Demcizumab (Anti-DLL4) in Patients with Previously Treated Solid Tumors

David C. Smith, Peter D. Eisenberg, Georgy Manikhas, Rashmi Chugh, Matthew A. Gubens, Robert J. Stagg, Ann M. Kapoun, Lu Xu, Jakob Dupont, Branimir Sikic
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2014) 20 (24): 6295–6303.
https://doi.org/10.1158/1078-0432.CCR-14-1373
Published: 14 December 2014
View article titled, A Phase I Dose Escalation and Expansion Study of the Anticancer Stem Cell Agent Demcizumab (Anti-DLL4) in Patients with Previously Treated Solid Tumors
Open the PDF for A Phase I Dose Escalation and Expansion Study of the Anticancer Stem Cell Agent Demcizumab (Anti-DLL4) in Patients with Previously Treated Solid Tumors in another window
Includes: Supplementary data
Journal Articles

A Phase I Study of the HSP90 Inhibitor Retaspimycin Hydrochloride (IPI-504) in Patients with Gastrointestinal Stromal Tumors or Soft-Tissue Sarcomas

Andrew J. Wagner, Rashmi Chugh, Lee S. Rosen, Jeffrey A. Morgan, Suzanne George, Michael Gordon, Joi Dunbar, Emmanuel Normant, David Grayzel, George D. Demetri
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2013) 19 (21): 6020–6029.
https://doi.org/10.1158/1078-0432.CCR-13-0953
Published: 31 October 2013
View article titled, A Phase I Study of the HSP90 Inhibitor Retaspimycin Hydrochloride (IPI-504) in Patients with Gastrointestinal Stromal Tumors or Soft-Tissue Sarcomas
Open the PDF for A Phase I Study of the HSP90 Inhibitor Retaspimycin Hydrochloride (IPI-504) in Patients with Gastrointestinal Stromal Tumors or Soft-Tissue Sarcomas in another window
Includes: Supplementary data
Journal Articles

Efficacy of Imatinib in Aggressive Fibromatosis: Results of a Phase II Multicenter Sarcoma Alliance for Research through Collaboration (SARC) Trial

Rashmi Chugh, J. Kyle Wathen, Shreyaskumar R. Patel, Robert G. Maki, Paul A. Meyers, Scott M. Schuetze, Dennis A. Priebat, Dafydd G. Thomas, Jon A. Jacobson, Brian L. Samuels, Robert S. Benjamin, Laurence H. Baker
Journal: Clinical Cancer Research
Clin Cancer Res (2010) 16 (19): 4884–4891.
https://doi.org/10.1158/1078-0432.CCR-10-1177
Published: 29 September 2010
View article titled, Efficacy of Imatinib in Aggressive Fibromatosis: Results of a Phase II Multicenter Sarcoma Alliance for Research through Collaboration (SARC) Trial
Open the PDF for Efficacy of Imatinib in Aggressive Fibromatosis: Results of a Phase II Multicenter Sarcoma Alliance for Research through Collaboration (SARC) Trial in another window